Jamie E Flerlage1, Monika L Metzger2, Jianrong Wu3, John C Panetta4. 1. Department of Oncology, St. Jude Children's Research Hospital, The University of Tennessee Health Science Center, 262 Danny Thomas Pl, Mailstop 260, Memphis, TN, 38105, USA. jamie.flerlage@stjude.org. 2. Department of Oncology, St. Jude Children's Research Hospital, The University of Tennessee Health Science Center, 262 Danny Thomas Pl, Mailstop 260, Memphis, TN, 38105, USA. 3. Department of Biostatistics, St. Jude Children's Research Hospital, The University of Tennessee Health Science Center, Memphis, TN, USA. 4. Pharmaceutical Sciences, St. Jude Children's Research Hospital, The University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
PURPOSE: Because of the observed success of phase I/II trials, the novel anti-CD30 agent brentuximab vedotin is now being evaluated as a frontline agent in the high-risk pediatric Hodgkin lymphoma trial HLHR13. The objectives of this study were to evaluate the pharmacokinetic variability during weekly dosing of 1.2 mg/kg of brentuximab vedotin, determine factors that may explain this variability, compare our drug exposure with published data, and evaluate toxicity of brentuximab vedotin in the pediatric population. METHODS: Brentuximab vedotin, MMAE and anti-therapeutic antibody levels were measured in the serum samples of 16 pediatric patients with Hodgkin lymphoma. A compartmental pharmacokinetic model was fit to the data by using nonlinear mixed-effects modeling. RESULTS: Clearance and volume of brentuximab vedotin were significantly correlated with weight (p < .001), which was responsible for over 60% of the parameters inter-individual variability. Clearance and volume were higher in boys compared to girls (p = 0.08 and p = 0.03, respectively). Brentuximab vedotin's AUC and C max were lower in our pediatric study than those reported in adult studies (25 and 11%, respectively). Toxicity was comparable to that of the standard-of-care backbone using vincristine instead of brentuximab vedotin. The sera of all 16 patients remained negative for anti-therapeutic antibodies during and at the end of therapy. CONCLUSIONS: As in previous studies, weight continues to be the most significant factor explaining brentuximab vedotin's pharmacokinetic variability in pediatric patients. Exposure to weekly dosing appears to be safe and tolerable in pediatric patients.
PURPOSE: Because of the observed success of phase I/II trials, the novel anti-CD30 agent brentuximabvedotin is now being evaluated as a frontline agent in the high-risk pediatric Hodgkin lymphoma trial HLHR13. The objectives of this study were to evaluate the pharmacokinetic variability during weekly dosing of 1.2 mg/kg of brentuximabvedotin, determine factors that may explain this variability, compare our drug exposure with published data, and evaluate toxicity of brentuximabvedotin in the pediatric population. METHODS:Brentuximabvedotin, MMAE and anti-therapeutic antibody levels were measured in the serum samples of 16 pediatric patients with Hodgkin lymphoma. A compartmental pharmacokinetic model was fit to the data by using nonlinear mixed-effects modeling. RESULTS: Clearance and volume of brentuximabvedotin were significantly correlated with weight (p < .001), which was responsible for over 60% of the parameters inter-individual variability. Clearance and volume were higher in boys compared to girls (p = 0.08 and p = 0.03, respectively). Brentuximabvedotin's AUC and C max were lower in our pediatric study than those reported in adult studies (25 and 11%, respectively). Toxicity was comparable to that of the standard-of-care backbone using vincristine instead of brentuximabvedotin. The sera of all 16 patients remained negative for anti-therapeutic antibodies during and at the end of therapy. CONCLUSIONS: As in previous studies, weight continues to be the most significant factor explaining brentuximabvedotin's pharmacokinetic variability in pediatric patients. Exposure to weekly dosing appears to be safe and tolerable in pediatric patients.
Authors: R Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur Journal: Clin Cancer Res Date: 2012-09-07 Impact factor: 12.531
Authors: Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Ajay K Gopal; Radhakrishnan Ramchandren; Owen A O'Connor; Robert B Berryman; Ranjana H Advani; Robert Chen; Scott E Smith; Maureen Cooper; Achim Rothe; Jeffrey V Matous; Laurie E Grove; Jasmine Zain Journal: Blood Date: 2012-04-17 Impact factor: 22.113
Authors: Kara M Kelly; David Hodgson; Burton Appel; Lu Chen; Peter D Cole; Terzah Horton; Frank G Keller Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: William D Hedrich; Tamer E Fandy; Hossam M Ashour; Hongbing Wang; Hazem E Hassan Journal: Clin Pharmacokinet Date: 2018-06 Impact factor: 6.447
Authors: Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly Journal: Lancet Oncol Date: 2018-08-16 Impact factor: 41.316
Authors: Ted G Xiao; Jared A Weis; F Scott Gayzik; Alexandra Thomas; Akiko Chiba; Metin N Gurcan; Umit Topaloglu; Abhilash Samykutty; Lacey R McNally Journal: Photoacoustics Date: 2018-07-27